Coverage of Biotech Equities -- Amarin, Cytori Therapeutics, Medivation, Sangamo BioSciences, and Immunomedics

LONDON, February 5, 2015 /PRNewswire/ --

Investor-Edge has initiated coverage on the following equities: Amarin Corporation PLC (NASDAQ: AMRN), Cytori Therapeutics Inc. (NASDAQ: CYTX), Medivation Inc. (NASDAQ: MDVN), Sangamo BioSciences Inc. (NASDAQ: SGMO), and Immunomedics Inc. (NASDAQ: IMMU). Free research report on Amarin can be accessed at http://get.Investor-Edge.com/pdf/?c=Amarin&d=05-Feb-2015&s=AMRN. The US markets on Wednesday, February 04, 2015, mostly ended on a negative note as the Dow Jones Industrial Average finished at 17,673.02, up 0.04% and the NASDAQ Composite closed at 4,716.70, down 0.23%. The S&P 500 finished the session 0.42% lower at 2,041.51. During the trading session, six out of ten sectors finished on a lower note. The S&P 500 Health Care Sector Index ended the day at 800.54, down 1.35%, whereas the index has advanced 2.67% in the previous three months. Register for your complimentary reports at the links given below.  

On Wednesday, Amarin Corp. PLC's stock gained 2.94%, to close the session at $1.05. The stock recorded a trading volume of 1.66 million shares, above its three months average volume of 1.57 million shares. The company's shares oscillated between $1.02 and $1.09 during the session. Over the previous three trading sessions and over the past three months, Amarin Corp. PLC's shares have gained 2.94% and 13.99%, respectively. However, the stock has lost 7.08% in the last one month. The stock is trading below its 50-day and 200-day moving averages. Amarin Corp. PLC's 200-day moving average of $1.35 is above its 50-day moving average of $1.07. Additionally, the stock has a Relative Strength Index (RSI) of 46.78. Sign up and read the free notes on AMRN at:

http://get.Investor-Edge.com/pdf/?c=Amarin&d=05-Feb-2015&s=AMRN

On Wednesday, shares in Cytori Therapeutics Inc. recorded a trading volume of 0.48 million shares, lower than its three months average volume of 1.37 million shares. The stock ended the day at $0.46, which was 4.17% below its previous day's closing of $0.48, and registered an intraday range of $0.46 and $0.48. Cytori Therapeutics Inc.'s shares have declined 11.54% in the last one month, 4.17% in the previous three months, and 82.10% in the past one year. The stock is trading below its 50-day and 200-day moving averages of $0.48 and $1.32, respectively. Furthermore, shares of Cytori Therapeutics Inc. have an RSI of 48.60. The complimentary notes on CYTX can be downloaded as in PDF format at:

http://get.Investor-Edge.com/pdf/?c=Cytori%20Therapeutics&d=05-Feb-2015&s=CYTX

Medivation Inc.'s stock edged 0.74% lower to end Wednesday's session at $100.66. The stock recorded a trading volume of 0.96 million shares, below its three months average volume of 1.10 million shares. The company's shares fluctuated between $97.59 and $101.49 during the session. Shares of the company traded at a PE ratio of 71.39. Medivation Inc.'s shares have surged 31.44% in the past one year. However, the stock has fallen by 1.11% over the last one month and 3.05% in the previous three months. The company's shares are trading above their 200-day moving average. Medivation Inc.'s 50-day moving average of $106.72 is above its 200-day moving average of $89.37. Additionally, the stock has an RSI of 42.06. Register for free on Investor-Edge and access the latest research on MDVN at:

http://get.Investor-Edge.com/pdf/?c=Medivation&d=05-Feb-2015&s=MDVN

On Wednesday, shares in Sangamo BioSciences Inc. fluctuated between $12.10 and $12.93 before ending the session 0.08% higher at $12.80. The stock reported a trading volume of 1.06 million shares, higher than its three months average volume of 0.88 million shares. Although Sangamo BioSciences Inc.'s stock has advanced 0.08% in the previous three trading sessions and 11.21% in the last three months, it has lost 16.18% in the past one month. The stock is trading below its 50-day and 200-day moving averages of $13.80 and $13.16, respectively. Moreover, shares of Sangamo BioSciences Inc. have an RSI of 39.03. The complete research on SGMO is available for free at:

http://get.Investor-Edge.com/pdf/?c=Sangamo%20BioSciences&d=05-Feb-2015&s=SGMO

Immunomedics Inc.'s stock finished Wednesday's session 2.79% lower at $4.88. A total of 0.88 million shares were traded, which was above its three months average volume of 0.72 million shares. The stock vacillated between $4.81 and $5.01 during the session. Over the last one month and over the past three months, Immunomedics Inc.'s shares have gained 2.09% and 27.42%, respectively. Additionally, in the past one year, the stock has advanced 4.27%. The company's shares are trading above their 50-day and 200-day moving averages. Moreover, the stock's 50-day moving average of $4.57 is greater than its 200-day moving average of $3.78. Immunomedics Inc.'s stock has an RSI of 55.62. Free in depth research on IMMU is available at:

http://get.Investor-Edge.com/pdf/?c=Immunomedics&d=05-Feb-2015&s=IMMU

About Investor-Edge.com 

At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

===============

EDITOR'S NOTES:

===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Investor-Edge

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED